Molecular Partners (NASDAQ:MOLN – Get Free Report) and INmune Bio (NASDAQ:INMB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Profitability
This table compares Molecular Partners and INmune Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molecular Partners | -1,043.01% | -39.31% | -35.46% |
| INmune Bio | N/A | -117.48% | -78.96% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Molecular Partners and INmune Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molecular Partners | 0 | 0 | 1 | 1 | 3.50 |
| INmune Bio | 0 | 0 | 5 | 1 | 3.17 |
Volatility and Risk
Molecular Partners has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Insider & Institutional Ownership
26.5% of Molecular Partners shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 35.2% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Molecular Partners and INmune Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Molecular Partners | $4.97 million | 31.20 | -$69.04 million | ($1.81) | -2.12 |
| INmune Bio | $50,000.00 | 3,613.08 | -$30.01 million | ($1.93) | -4.07 |
INmune Bio has lower revenue, but higher earnings than Molecular Partners. INmune Bio is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.
Summary
Molecular Partners beats INmune Bio on 8 of the 14 factors compared between the two stocks.
About Molecular Partners
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
